Inspire Pharmaceuticals (Nasdaq: ISPH) reported a $17.6 million loss for its most recent quarter, most of which was caused by the company’s restructuring.

A year ago, Inspire lost $14.8 million.

Drug giant Merck is in the process of buying Inspire for $430 million.

Inspire chose to focus on eye care drugs in February and laid off 65 workers. The company took a $12.2 million charge to cover the restructuring.

Merck announced its intention to buy Inspire in April.

For the full financial report, read here.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.